You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Rare disease
Chronic management of pulmonary embolism in thromboangiitis obliterans
  1. Mariana Martinho1,
  2. Ana Glória Fonseca2,
  3. Rita Calé1 and
  4. Helder Horta Pereira1
  1. 1Cardiology, Hospital Garcia de Orta EPE, Almada, Setúbal, Portugal
  2. 2Internal Medicine, Hospital Garcia de Orta EPE, Almada, Setúbal, Portugal
  1. Correspondence to Professor Helder Horta Pereira; hhpereira{at}gmail.com

Abstract

Thromboangiitis obliterans (TAO), also known as Buerger’s disease, is a rare small vessel vasculitis that is associated with an increased risk of arterial occlusion. Although venous thromboembolism has been described, the risk of its recurrence and the best long-term anticoagulation management is not known. Considering this, we would like to share our experience with two patients admitted to our hospital with recurrent pulmonary embolism and previous diagnosis of TAO, aiming to discuss the indication for indefinite anticoagulation in this population.

  • Venous thromboembolism
  • Cardiovascular system

https://doi.org/10.1136/bcr-2022-252456

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors MM was responsible for data collection and manuscript writing. AGF was associated with patient management and manuscript revision. RC revised the final manuscript. HHP revised the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.